Psychotropic Medications to Patients With Treatment-Resistant Depression in France
Author(s)
Alexandre Vimont, MSc1, Margot Biscond, PhD, MSc2, Henri Leleu, PhD, MD3, marina sanchez, PhD, MSc4, nicolas hoertel, PhD, MD4, pierre-michel llorca, PhD, MD5.
1Senior analyst, Public Health Expertise, paris, France, 2Public Health Expertise, Paris, France, 3public health expertise, Paris, France, 4AP-HP, DMU Psychiatry and Addictology, Corentin-Celton Hospital, Paris, France, 5Department of Psychiatry, CHU Clermont-Ferrand, Paris, France.
1Senior analyst, Public Health Expertise, paris, France, 2Public Health Expertise, Paris, France, 3public health expertise, Paris, France, 4AP-HP, DMU Psychiatry and Addictology, Corentin-Celton Hospital, Paris, France, 5Department of Psychiatry, CHU Clermont-Ferrand, Paris, France.
OBJECTIVES: This study aimed at estimating prevalence of Treatment-Resistant Depression (TRD) and investigating treatment patterns in real-life settings.
METHODS: Adult with a TRD episode in 2019 were identified from a representative sample of the French population. After exclusion of patients with psychotic or bipolar disorders, Parkinson's disease, and dementia, TRD was defined by 3 successive sequences of different antidepressants (AD), or the dispensing of several different AD together, or an AD with an augmenting agent over the same treatment period. The prevalence rate was estimated, and treatment patterns were described by treatment class and molecule
RESULTS: 66,810 patients were identified with TRD, accounting for 23.9% of patients treated for depression. Mean age was 56 years with 63.7% of women. Standardized prevalence was estimated at 35.1 per 10 000 patients, and 25.8 per 10,000 patients when excluding patients probably treated for another primary diagnosis than depression. Association of an AD with an antipsychotic was the most frequently used strategy, with SSRIs and second-generation antipsychotics being the most often prescribed
CONCLUSIONS: This study provides robust population-based estimates of the prevalence of TRD in the French population. Description of treatment patterns highlight the widespread use of second-generation antipsychotics as augmenting agent of antidepressants
METHODS: Adult with a TRD episode in 2019 were identified from a representative sample of the French population. After exclusion of patients with psychotic or bipolar disorders, Parkinson's disease, and dementia, TRD was defined by 3 successive sequences of different antidepressants (AD), or the dispensing of several different AD together, or an AD with an augmenting agent over the same treatment period. The prevalence rate was estimated, and treatment patterns were described by treatment class and molecule
RESULTS: 66,810 patients were identified with TRD, accounting for 23.9% of patients treated for depression. Mean age was 56 years with 63.7% of women. Standardized prevalence was estimated at 35.1 per 10 000 patients, and 25.8 per 10,000 patients when excluding patients probably treated for another primary diagnosis than depression. Association of an AD with an antipsychotic was the most frequently used strategy, with SSRIs and second-generation antipsychotics being the most often prescribed
CONCLUSIONS: This study provides robust population-based estimates of the prevalence of TRD in the French population. Description of treatment patterns highlight the widespread use of second-generation antipsychotics as augmenting agent of antidepressants
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH195
Topic
Epidemiology & Public Health, Real World Data & Information Systems
Disease
Mental Health (including addition)